๐€๐ซ๐ž ๐ฒ๐จ๐ฎ ๐ฌ๐ญ๐ซ๐ฎ๐ ๐ ๐ฅ๐ข๐ง๐  ๐ฐ๐ข๐ญ๐ก ๐ญ๐ก๐ž ๐œ๐จ๐ฆ๐ฉ๐ฅ๐ž๐ฑ ๐ซ๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐ข๐จ๐ง๐ฌ ๐ฌ๐ž๐ญ ๐›๐ฒ ๐ญ๐ก๐ž ๐…๐ƒ๐€ ๐š๐ง๐ ๐„๐Œ๐€?

ADRES Webinar on Pre-Approval Inspection Readiness

๐“๐ก๐ข๐ฌ ๐ฐ๐ž๐›๐ข๐ง๐š๐ซ ๐Ÿ๐จ๐œ๐ฎ๐ฌ ๐จ๐ง ๐ข๐ง๐ฌ๐ฉ๐ž๐œ๐ญ๐ข๐จ๐ง ๐ซ๐ž๐š๐๐ข๐ง๐ž๐ฌ๐ฌ, providing comprehensive insights into the necessary activities and best practices to face regulatory inspections confidently.

This webinar caters explicitly to companies involved in the clinical development of Pharmaceuticals, biologics, and combination products.

We promise to demystify the process and equip you with actionable strategies to transform uncertainty into confidence.

Whether it’s understanding the implications of a Voluntary Action Indicated (VAI) status from a key subcontractor or simply refining your readiness checklist, we’ve got you covered.

If you have any questions or need further assistance, please feel free to reach out to us at https://adres.bio/contact-us.

Join our YouTube channel, where you can find our original videos, with relevant information.


The end of animal testing in America?

Not so fast…
President Biden created a buzz when he signed a law, eliminating the requirement to test a drug or medical device on animals before testing their effectiveness and safety in humans. But the road is still long and winding, as non-animal technologies still need to be proven as an effective tool for evaluating both safety and effectiveness.
As part of the FDA efforts to support its Toxicology Working Group in advancing the goals of identifying new technologies that could potentially improve toxicity predictivity as well as to support animal 3Rs (Replacement, Reduction, and Refinement), the agency formed the Alternative Methods Working Group. This program focuses on opportunities for evolving and innovative technologies to advance useful tools for testing the effectiveness and safety of therapeutic products, such as microphysiological systems (MPS).


One example of such systems are organoids, self-organized, three-dimensional tissue cultures derived from stem cells, that can divide indefinitely and form tiny structures that resemble miniature organs composed of many cell types. Researchers have been able to produce organoids that resemble the brain, kidney, lung, intestine, stomach, and liver, with many more on the way.
Another subset class of MPS is organs-on-a-chip, which consists of a miniaturized physiological environment engineered to yield and/or analyze functional tissue units capable of modeling targeted organ-level responses.
In contrast to the US, the principle of the 3Rs has been present in spirit in EU legislation, from as early as 1986, and it was made a legal requirement in 2010 in Directive 2010/63/EU.
From our experience and correspondence with both the FDA and EMA, the latter seems much more committed to the 3Rs approach around in vivo testing. The EMA will more often accept proof of concept studies solely based on in vitro or in silico tests and may require only rodents for toxicological studies, not just for biologicals.
Letโ€™s hope the FDA will manage to commit to this advanced approach sooner than we assume ๐Ÿ˜‰
 

Feel free to Contact us for any questions and consultations, weโ€™ll be happy to assist!

GMP Annex 1 โ€“ Final Revision

๐“๐ก๐ž ๐„๐ฎ๐ซ๐จ๐ฉ๐ž๐š๐ง ๐”๐ง๐ข๐จ๐ง ๐ซ๐ž๐œ๐ž๐ง๐ญ๐ฅ๐ฒ ๐ข๐ฌ๐ฌ๐ฎ๐ž๐ ๐ญ๐ก๐ž ๐Ÿ๐ข๐ง๐š๐ฅ ๐ซ๐ž๐ฏ๐ข๐ฌ๐ข๐จ๐ง ๐จ๐Ÿ ๐†๐Œ๐ ๐€๐ง๐ง๐ž๐ฑ 1: ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ž ๐จ๐Ÿ ๐’๐ญ๐ž๐ซ๐ข๐ฅ๐ž ๐Œ๐ž๐๐ข๐œ๐ข๐ง๐š๐ฅ ๐๐ซ๐จ๐๐ฎ๐œ๐ญ๐ฌ, ๐•๐จ๐ฅ. 4 ๐Ÿ๐จ๐ซ 2022.

Many of the changes are more stringent than in previous versions. For example:

โ€ข Separate change rooms are required for entering and leaving production areas if the Contamination Control Strategy (CCS) indicates the risk of contamination is high

โ€ข For cleanroom qualification and EM, all grades are required to measure the total particles equal to or greater 0.5 and 5 ยตm/m3, with instructions to consider 5ยตm particles measurements where limits are not specified

โ€ข For Interventions, all non-qualified interventions should be recorded in the batch record, authorized by the quality unit, and assessed.

We thought the most interesting change required the bioburden samples be taken prior to the first filter if a redundant filtration setup is used.

These are just a few of the changes to the annex. To learn how these and other updates could impact your operations, download our GMP Annex 1 guidelines and reach out.


FDAโ€™s New Advanced Therapies โ€œSuper Officeโ€ to Benefit Medical Startups – Biotech Regulatory Solutions.

In mid-September, the US Food and Drug Administration (FDA) announced that the Office of Tissues and Advanced Therapies (OTAT) will become the Office of Therapeutic Products (OTP). The organizational changes, which were approved in August and went into effect on September 16, are far more than just a name change.ย In this era of rapid advancement, biotech regulatory consulting plays a crucial role in navigating FDA changes.

OTP, which like OTAT is part of the FDAโ€™s Center for Biologics Evaluation and Research (CBER), will be elevated to a Super Office. This will allow CBER to manage the program at a macro level and better position the center to address an ever-changing public health landscape. These changes are not just significant locally but will influence global regulatory services and their strategies.

The new organizational changes will improve functional alignment, increase the review capabilities of the organization, and enhance expertise on new cell and gene therapies. It will also include more full-time staff and supervisory positions, as well as avoid the need for continual reorganizations.

This organizational change is welcome news to startups, who often encounter delays while waiting for FDA approval. Super Offices, which have been created over the past decade, are often more efficient as they tend to optimize combined functions that had been taking place in separate departments.

At ADRES, we believe that biopharmaceutical companies and startups involved in the development of cell and gene therapy will see a far more streamlined approval process, with more transparency in the process. Companies should expect to see an expedited drug development and review process, particularly for promising pipeline products.

Discover how we can help you get to market faster! Talk to us today.

Skip to content